Cargando…

612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries

BACKGROUND: Ceftolozane–tazobactam (C/T) is a combination of an antipseudomonal cephalosporin with a known β-lactamase inhibitor, with a potent in vitro activity against P. aeruginosa (Pae), without activity against carbapenemases. Among the mechanisms of resistance to C/T that have emerged, substit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mojica, Maria F, Rios, Rafael, De La Cadena, Elsa, Correa, Adriana, Diaz, Lorena, Millan, Lina V, Hernandez, Angie K, Reyes, Jinnethe, Hernández-Gómez, Cristhian, Radice, Marcela A, Castañeda-Méndez, Paulo, Jaime-Villalón, Diego A, Gales, Ana C, Munita, Jose M, López, Catalina, Rojas Rojas, Monica Maria, Virginia Villegas, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810906/
http://dx.doi.org/10.1093/ofid/ofz360.681
_version_ 1783462349587349504
author Mojica, Maria F
Rios, Rafael
De La Cadena, Elsa
Correa, Adriana
Diaz, Lorena
Millan, Lina V
Hernandez, Angie K
Reyes, Jinnethe
Hernández-Gómez, Cristhian
Radice, Marcela A
Castañeda-Méndez, Paulo
Jaime-Villalón, Diego A
Gales, Ana C
Munita, Jose M
López, Catalina
Rojas Rojas, Monica Maria
Virginia Villegas, Maria
author_facet Mojica, Maria F
Rios, Rafael
De La Cadena, Elsa
Correa, Adriana
Diaz, Lorena
Millan, Lina V
Hernandez, Angie K
Reyes, Jinnethe
Hernández-Gómez, Cristhian
Radice, Marcela A
Castañeda-Méndez, Paulo
Jaime-Villalón, Diego A
Gales, Ana C
Munita, Jose M
López, Catalina
Rojas Rojas, Monica Maria
Virginia Villegas, Maria
author_sort Mojica, Maria F
collection PubMed
description BACKGROUND: Ceftolozane–tazobactam (C/T) is a combination of an antipseudomonal cephalosporin with a known β-lactamase inhibitor, with a potent in vitro activity against P. aeruginosa (Pae), without activity against carbapenemases. Among the mechanisms of resistance to C/T that have emerged, substitutions in the Pseudomonal-derived cephalosporinase (PDC), in AmpR, and in some ESBLs, are the most commonly described. The aim of this study was to identify the molecular mechanisms responsible for the in vitro non-susceptibility (NS) to C/T in a group of clinical Pae strains from Latin America. METHODS: Clinical Pae isolates (n = 508) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to C/T were determined by standard broth microdilution and interpreted according to CLSI M100 S28 breakpoints. Production of carbapenemases in Pae isolates displaying NS to C/T was assessed by carbaNP® followed by PCR to detect blaKPC, blaNDM-1, blaVIM and blaIMP. Illumina whole-genome sequencing (WGS) was performed for isolates in which NS to C/T was not mediated by carbapenemases. The presence of mutations in PDC, AmpR, oprD and dacB as compared with PAO1, was evaluated. RESULTS: According to the CLSI breakpoints, 162/508 (32%) Pae isolates demonstrated NS to C/T. Due to the absence of growth, only 151/162 were further processed. Table 1 summarizes the results obtained by carbaNP®, PCR and WGS performed on these isolates. In 53% of the isolates, NS to C/T was explained by the production of at least one carbapenemase, KPC or VIM. WGS revealed that in addition to substitutions in PDC and AmpR, some isolates carried mutations in oprD and dacB (encoding PBP4) genes. The molecular mechanism of resistance in 4/56 isolates is yet to be determined. CONCLUSION: Carbapenemase production is the most common mechanism of resistance to C/T detected in this study. VIM and KPC were detected in equal proportions, while none of the isolates was found to carry IMP or NDM. Further studies are warranted to establish the role of the novel substitutions found in PDC and AmpR, as well as the degree to which the mutations found in oprD and dacB contribute to the NS phenotype in some isolates. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810906
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68109062019-10-28 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries Mojica, Maria F Rios, Rafael De La Cadena, Elsa Correa, Adriana Diaz, Lorena Millan, Lina V Hernandez, Angie K Reyes, Jinnethe Hernández-Gómez, Cristhian Radice, Marcela A Castañeda-Méndez, Paulo Jaime-Villalón, Diego A Gales, Ana C Munita, Jose M López, Catalina Rojas Rojas, Monica Maria Virginia Villegas, Maria Open Forum Infect Dis Abstracts BACKGROUND: Ceftolozane–tazobactam (C/T) is a combination of an antipseudomonal cephalosporin with a known β-lactamase inhibitor, with a potent in vitro activity against P. aeruginosa (Pae), without activity against carbapenemases. Among the mechanisms of resistance to C/T that have emerged, substitutions in the Pseudomonal-derived cephalosporinase (PDC), in AmpR, and in some ESBLs, are the most commonly described. The aim of this study was to identify the molecular mechanisms responsible for the in vitro non-susceptibility (NS) to C/T in a group of clinical Pae strains from Latin America. METHODS: Clinical Pae isolates (n = 508) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to C/T were determined by standard broth microdilution and interpreted according to CLSI M100 S28 breakpoints. Production of carbapenemases in Pae isolates displaying NS to C/T was assessed by carbaNP® followed by PCR to detect blaKPC, blaNDM-1, blaVIM and blaIMP. Illumina whole-genome sequencing (WGS) was performed for isolates in which NS to C/T was not mediated by carbapenemases. The presence of mutations in PDC, AmpR, oprD and dacB as compared with PAO1, was evaluated. RESULTS: According to the CLSI breakpoints, 162/508 (32%) Pae isolates demonstrated NS to C/T. Due to the absence of growth, only 151/162 were further processed. Table 1 summarizes the results obtained by carbaNP®, PCR and WGS performed on these isolates. In 53% of the isolates, NS to C/T was explained by the production of at least one carbapenemase, KPC or VIM. WGS revealed that in addition to substitutions in PDC and AmpR, some isolates carried mutations in oprD and dacB (encoding PBP4) genes. The molecular mechanism of resistance in 4/56 isolates is yet to be determined. CONCLUSION: Carbapenemase production is the most common mechanism of resistance to C/T detected in this study. VIM and KPC were detected in equal proportions, while none of the isolates was found to carry IMP or NDM. Further studies are warranted to establish the role of the novel substitutions found in PDC and AmpR, as well as the degree to which the mutations found in oprD and dacB contribute to the NS phenotype in some isolates. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810906/ http://dx.doi.org/10.1093/ofid/ofz360.681 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Mojica, Maria F
Rios, Rafael
De La Cadena, Elsa
Correa, Adriana
Diaz, Lorena
Millan, Lina V
Hernandez, Angie K
Reyes, Jinnethe
Hernández-Gómez, Cristhian
Radice, Marcela A
Castañeda-Méndez, Paulo
Jaime-Villalón, Diego A
Gales, Ana C
Munita, Jose M
López, Catalina
Rojas Rojas, Monica Maria
Virginia Villegas, Maria
612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
title 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
title_full 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
title_fullStr 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
title_full_unstemmed 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
title_short 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
title_sort 612. molecular mechanisms leading to ceftolozane–tazobactam resistance in clinical isolates of pseudomonas aeruginosa from five latin american countries
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810906/
http://dx.doi.org/10.1093/ofid/ofz360.681
work_keys_str_mv AT mojicamariaf 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT riosrafael 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT delacadenaelsa 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT correaadriana 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT diazlorena 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT millanlinav 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT hernandezangiek 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT reyesjinnethe 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT hernandezgomezcristhian 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT radicemarcelaa 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT castanedamendezpaulo 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT jaimevillalondiegoa 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT galesanac 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT munitajosem 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT lopezcatalina 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT rojasrojasmonicamaria 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries
AT virginiavillegasmaria 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries